The State of the Medical Marijuana Market
In the 1960s and 70s, pot smokers were warned that marijuana could cause schizophrenia, among other mental disorders. Today, it’s lawmakers and government officials who exhibit symptoms of that condition. On August 11, 2016, the Drug Enforcement Administration (DEA) announced that it would allow more research into marijuana, and would expand the number of sites that can grow cannabis for research. At the same time, the agency rejected requests from several sectors, including The Epilepsy Foundation, that it relax the classification of cannabis from Schedule 1, as a dangerous, highly addictive drug with no medical use. Bummer, man. Today, 25 states have a medical or recreational cannabis... Read More »Third Quarter 2016 Shows Signs of Slowing
Eight months into the year is a good time to take stock of the state of the healthcare M&A market. On the whole, volume and value look to be stronger than last year. The first eight months of 2016 show a combined total of 1,019 transactions, compared with 1,005 in the same period in 2015, a 1% difference. Five of the first eight months in 2016 have posted higher transaction totals than the same months in 2015. Deal values have to be examined more closely, owing to the mega-deals that can create huge month-to-month fluctuations. Total dollars spent in the first eight months of 2016 are approximately $196 billion. In the same period in 2015, spending reached nearly $338 billion, thanks... Read More »Big Pharma Pays Big for Biotech Pipelines
The pharmaceutical industry has largely given up on in-house research and development, saying that the R&D timeline is too costly, long and uncertain to fund with shareholders’ money. The industry has gone from bolt-on acquisitions of smaller companies with marketed products to battling it out for clinical-stage drug candidates. What’s surprised some industry observers is that these acquirers are now targeting early-stage and even pre-clinical drug candidates, to boost their own production pipelines, but as a way to stymie the competition, too. Pharmaceutical mergers and acquisitions hit a peak in 2014, with 188 deals (up 25% year-over-year) and $213.3 billion in spending (up 220%... Read More »Busy Day for Bacterial Infection Drugs
On August 23rd, two separate deals occurred involving licenses to drug candidates for the treatment of serious infections. Productos Científicos S.A. de C.V. (PC), a leading privately-held Mexican pharmaceutical company, purchased a license to Taigexyn® in Latin America from privately-held TaiGen Biotechnology Company Limited. Taigexyn® (nemonoxacin) is a novel antibiotic for the treatment of bacterial infections, including those caused by drug resistant bacteria, which has proven its efficacy in Phase I, II and III clinical studies. According to IMS Health, Latin-America’s pharmaceutical market is projected to grow 9-12% from 2016-2020, faster than the projected 3-6% in more developed... Read More »Pfizer Buys Medivation and More
Forget those early- to mid-stage clinical candidates. Pfizer Inc. (NYSE: PFE) jumped the line with its $13.5 billion deal for oncology drug maker Medivation Inc. (NASDAQ: MDVN). The target’s primary product is XTANDI® (enzalutamide), an androgen receptor inhibitor, the leading novel hormone therapy for the treatment of prostate cancer. Pfizer will pay $81.50 per share in existing cash, a 21% premium to Medivation’s closing stock price on Friday, August 19, 2016. This deal ends months of bidding for Medivation, which began in April with Sanofi SA’s $52.50 per share (about $9 billion) offer. Medivation turned down the overture, and Sanofi eventually raised its bid to $58.50... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
